​

Kyntra Bio Stock (NASDAQ:KYNB)

ForecastRevenueFinancialsChartTranscripts
Kyntra Bio by TradingView

Previous Close

$7.61

52W Range

$6.32 - $12.60

50D Avg

$7.03

200D Avg

$8.32

Market Cap

$29.73M

Avg Vol (3M)

$18.47K

Beta

0.97

Div Yield

-

KYNB Company Profile

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

34

IPO Date

Nov 14, 2014

Website

KYNB Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Drug Product Revenue$5.85M$27.67M$18.75M

Fiscal year ends in Dec 25 | Currency in USD

KYNB Financial Summary

Dec 25Dec 24Dec 23
Revenue$6.44M$29.62M$46.80M
Operating Income$-45.90M$-150.42M$-322.72M
Net Income$183.45M$-47.58M$-284.23M
EBITDA$-45.90M$-142.43M$-305.20M
Basic EPS$45.37$-0.48$-2.92
Diluted EPS$45.37$-0.48$-2.92

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 11, 26 | 5:00 PM
Q4 25Mar 16, 26 | 5:00 PM
Q3 25Nov 10, 25 | 5:00 PM

Peer Comparison

TickerCompany
MRSNMersana Therapeutics, Inc.
OKUROnKure Therapeutics, Inc.
CELUCelularity Inc.
TPSTTempest Therapeutics, Inc.
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
XFORX4 Pharmaceuticals, Inc.
ALGSAligos Therapeutics, Inc.